CUV — Clinuvel Pharmaceuticals Income Statement

0.000.00%

Last trade - 00:00

HealthcareBalancedSmall CapHigh Flyer

Annual income statement for Clinuvel Pharmaceuticals, fiscal year end - June 30th, AUD millions except per share, conversion factor applied.

	R2020 June 30th	2021 June 30th	2022 June 30th	2023 June 30th	2024 June 30th
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	ARS	ARS	ARS	ARS	ARS
Standards:	IFRS	IFRS	IFRS	IFRS	IFRS
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	33.1	48.3	66.2	82.2	95.5
Cost of Revenue
Gross Profit	32.3	50.2	64.8	89.9	96.6
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Unusual Expense / Income
Total Operating Expenses	20.2	19.6	30.2	34.2	39.6
Operating Profit	12.9	28.7	36	48	55.9
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	11.5	25.7	34.3	45.6	50.7
Provision for Income Taxes
Net Income After Taxes	15.1	24.7	20.9	30.6	35.6
Net Income Before Extraordinary Items
Net Income	15.1	24.7	20.9	30.6	35.6
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	15.1	24.7	20.9	30.6	35.6
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	0.297	0.479	0.4	0.59	0.691
Dividends per Share